LAS VEGAS, March 24, 2021 /PRNewswire/ -- DelveInsight's 'Exocrine Pancreatic Insufficiency Market' report offers detailed coverage of historical and forecasted EPI epidemiological analysis in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan) for the study period 2018-30.
In the 7MM, the Exocrine Pancreatic Insufficiency prevalence (which includes Acute & Chronic Pancreatitis, Cystic Fibrosis, Pancreatic Cancer (Unresectable)) was observed to be 453,756 in 2020, with the United States accounting for the highest patient pool. Further, the EPI prevalence is expected to increase attributable to several reasons during the forecast period (2021–2030).
As per the estimates, 65,754; 68,776; 11,792; and 26,204 patients were affected by Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis, and Unresectable Pancreatic Cancer in 2020 in Japan.
The mainstay of Exocrine Pancreatic Insufficiency treatment is Pancreatic Enzyme Replacement Therapy (PERT).
The FDA approved pancreatic enzyme products (PEPs) comprise Pertzye, Creon, Pancreaze, Zenpep and Viokace.
The Exocrine Pancreatic Insufficiency market size is expected to expand owing to factors like increasing EPI prevalent population, entry of Exocrine Pancreatic Insufficiency emerging therapies with novel targets and attractive pricing.
Anticipated launch of AzurRx BioPharma's MS1819-SD is expected to fuel the pace of EPI therapeutics market size growth.
However, the EPI pipeline is narrow and only a limited number of therapies are in the pipeline offering pharmaceutical companies immense opportunity to grab the share.
The Exocrine Pancreatic Insufficiency market report proffers a detailed analysis of treatment landscape, pipeline therapies, changing market landscape, individual market share of pipeline therapies, EPI market drivers, and market barriers, EPI market size during the study period 2018-30 in the 7MM).
The Exocrine Pancreatic Insufficiency report is created to uncover hidden opportunities in the EPI market landscape, help clients form collaborations and ink deals that give them a competitive advantage, and plan strategic moves to offer maximum returns.
Exocrine Pancreatic Insufficiency or Pancreatic exocrine insufficiency (PEI/EPI) is defined as inadequate activity or deficiency of the pancreatic enzymes within the intestinal lumen, resulting in maldigestion and malabsorption. PEI is the consequence of several different diseases which all share a common pathophysiologic end result of inadequate enzyme digestion.
Exocrine Pancreatic Insufficiency Epidemiological Analysis and Forecast
As per EPI epidemiological assessment, Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer are assumed to play the foremost role in the development of EPI. Besides, metabolic diseases (Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus), Schwachman–Diamond Syndrome, HIV/AIDS, impaired hormonal stimulation of exocrine pancreatic secretion by cholecystokinin (CCK), Celiac disease or inflammatory bowel disease (IBD) due to loss of intestinal brush border proteins, Ulcerative Colitis, Crohn's Disease, and small intestinal bacterial overgrowth the major causative agents for Exocrine Pancreatic Insufficiency (EPI).
The EPI treatment landscape primarily consists of pancreatic enzyme replacement therapy (PERT), lifestyle modifications (e.g., avoidance of fatty foods, limitation of alcohol intake, cessation of smoking, and consumption of a well-balanced diet), and vitamin supplementation (primarily the fat-soluble vitamins A, D, E, and K). Pancreatic enzyme replacement therapy (PERT) is the first-line therapeutic mainstay of the Exocrine Pancreatic Insufficiency therapeutics market.
Despite the availability of several approved PEPs, only limited data is available for clinical studies. Further, there is a need for better diagnostics modalities owing to the differential diagnosis of EPI as many of the EPI symptoms tend to overlap with other common gastrointestinal diseases (pancreatic and extrapancreatic disorders). Oftentimes, patients fail to respond to treatment despite optimal dosing of enzymes and clinical assessment. The financial burden of available therapies is also a huge concern impacting their uptake. Besides, lack of disease awareness and inadequate medical or healthcare facilities add to the market growth barriers.
However, to meet the prevailing unmet needs in the EPI market landscape, pharmaceutical companies like AzurRx BioPharma, Chiesi Pharmaceuticals among others are dynamically operating in the domain. DelveInsight estimates that the future of the Exocrine Pancreatic Insufficiency market is expected to incline towards extended therapies as well as more novel approaches. Although strict FDA policies guiding the approval of PERT products is assumed to be a constraint in the EPI market size growth.
Nevertheless, the launch of novel therapeutic agents in the EPI market are expected to propel market growth in the coming decade. An increase in the number of patients suffering from diseases such as chronic pancreatitis and cystic fibrosis, which are causative factors of EPI shall increase the Exocrine Pancreatic Insufficiency prevalence, thereby, offering an expanding patient pool to the pharma companies.
Get comprehensive historical and forecast analysis of Alopecia Areata Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Pfizer, Legacy Healthcare SA, Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Bioniz Therapeutics, LEO Pharma, Bristol-Myers Squibb, Eli Lilly and Company/Incyte Corporationand several others.
Get comprehensive historical and forecast analysis of CLBP Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Stayble Therapeutics, Asahi Kasei Pharma, AnGes MG, and others.
Get comprehensive historical and forecast analysis of Plaque Psoriasis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Bristol-Myers Squibb, Dermavant Sciences GmbH, Arcutis, Inc., Avillion LLP, Dermavant Sciences GmbH, and others.
Get comprehensive historical and forecast analysis of Plaque Psoriasis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Bio-Thera Solutions, RemeGen, Harbour BioMed, and others.
Get comprehensive historical and forecast analysis of Plaque Psoriasis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Novartis, and others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.